 | • レポートコード：MRC2012A6371 • 出版社/出版日：GlobalInfoResearch / 2020年12月24日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、神経線維腫症1型の世界市場を広く調査・分析し、今後の市場展望をまとめております。神経線維腫症1型の種類別市場規模（10mg、25mg）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：AstraZeneca、Merck ・地域別グローバル市場分析 2015年-2020年 ・神経線維腫症1型の北米市場（アメリカ、カナダ、メキシコ） ・神経線維腫症1型のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・神経線維腫症1型のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・神経線維腫症1型の南米市場（ブラジル、アルゼンチン） ・神経線維腫症1型の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：10mg、25mg ・用途別分析：病院、診療所、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The Neurofibromatosis Type 1 market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The global Neurofibromatosis Type 1 market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
Market segmentation
Neurofibromatosis Type 1 market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Neurofibromatosis Type 1 market has been segmented into
10 mg
25 mg
By Application, Neurofibromatosis Type 1 has been segmented into:
Hospitals
Clinics
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neurofibromatosis Type 1 market presented in the report. This section sheds light on the sales growth of different regional and country-level Neurofibromatosis Type 1 markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neurofibromatosis Type 1 market.
The report offers in-depth assessment of the growth and other aspects of the Neurofibromatosis Type 1 market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Neurofibromatosis Type 1 Market Share Analysis
Neurofibromatosis Type 1 competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neurofibromatosis Type 1 sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neurofibromatosis Type 1 sales, revenue and market share for each player covered in this report.
The major players covered in Neurofibromatosis Type 1 are:
AstraZeneca
Merck
Among other players domestic and global, Neurofibromatosis Type 1 market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neurofibromatosis Type 1 product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neurofibromatosis Type 1, with price, sales, revenue and global market share of Neurofibromatosis Type 1 in 2018 and 2019.
Chapter 3, the Neurofibromatosis Type 1 competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurofibromatosis Type 1 breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Neurofibromatosis Type 1 market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Neurofibromatosis Type 1 sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Neurofibromatosis Type 1 Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neurofibromatosis Type 1 Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 10 mg
1.2.3 25 mg
1.3 Market Analysis by Application
1.3.1 Overview: Global Neurofibromatosis Type 1 Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Overview of Global Neurofibromatosis Type 1 Market
1.4.1 Global Neurofibromatosis Type 1 Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca SWOT Analysis
2.1.4 AstraZeneca Product and Services
2.1.5 AstraZeneca Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck SWOT Analysis
2.2.4 Merck Product and Services
2.2.5 Merck Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Neurofibromatosis Type 1 Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Neurofibromatosis Type 1 Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Neurofibromatosis Type 1 Manufacturer Market Share in 2019
3.3.2 Top 6 Neurofibromatosis Type 1 Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Neurofibromatosis Type 1 Sales, Revenue and Market Share by Regions
4.1.1 Global Neurofibromatosis Type 1 Sales and Market Share by Regions (2015-2020)
4.1.2 Global Neurofibromatosis Type 1 Revenue and Market Share by Regions (2015-2020)
4.2 North America Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
4.3 Europe Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
4.5 South America Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Neurofibromatosis Type 1 Sales, Revenue and Market Share by Country
5.1.1 North America Neurofibromatosis Type 1 Sales and Market Share by Country (2015-2020)
5.1.2 North America Neurofibromatosis Type 1 Revenue and Market Share by Country (2015-2020)
5.2 United States Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
5.3 Canada Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
5.4 Mexico Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Neurofibromatosis Type 1 Sales, Revenue and Market Share by Country
6.1.1 Europe Neurofibromatosis Type 1 Sales and Market Share by Country (2015-2020)
6.1.2 Europe Neurofibromatosis Type 1 Revenue and Market Share by Country (2015-2020)
6.2 Germany Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
6.3 UK Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
6.4 France Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
6.5 Russia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
6.6 Italy Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Neurofibromatosis Type 1 Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Neurofibromatosis Type 1 Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Neurofibromatosis Type 1 Revenue and Market Share by Regions (2015-2020)
7.2 China Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
7.3 Japan Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
7.4 Korea Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
7.5 India Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
7.7 Australia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Neurofibromatosis Type 1 Sales, Revenue and Market Share by Country
8.1.1 South America Neurofibromatosis Type 1 Sales and Market Share by Country (2015-2020)
8.1.2 South America Neurofibromatosis Type 1 Revenue and Market Share by Country (2015-2020)
8.2 Brazil Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
8.3 Argentina Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Neurofibromatosis Type 1 Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Neurofibromatosis Type 1 Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Neurofibromatosis Type 1 Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
9.3 Turkey Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
9.4 Egypt Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
9.5 South Africa Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Neurofibromatosis Type 1 Sales and Market Share by Type (2015-2020)
10.2 Global Neurofibromatosis Type 1 Revenue and Market Share by Type (2015-2020)
10.3 Global Neurofibromatosis Type 1 Price by Type (2015-2020)
11 Global Neurofibromatosis Type 1 Market Segment by Application
11.1 Global Neurofibromatosis Type 1 Sales Market Share by Application (2015-2020)
11.2 Global Neurofibromatosis Type 1 Revenue Market Share by Application (2015-2020)
11.3 Global Neurofibromatosis Type 1 Price by Application (2015-2020)
12 Market Forecast
12.1 Global Neurofibromatosis Type 1 Sales, Revenue and Growth Rate (2021-2025)
12.2 Neurofibromatosis Type 1 Market Forecast by Regions (2021-2025)
12.2.1 North America Neurofibromatosis Type 1 Market Forecast (2021-2025)
12.2.2 Europe Neurofibromatosis Type 1 Market Forecast (2021-2025)
12.2.3 Asia-Pacific Neurofibromatosis Type 1 Market Forecast (2021-2025)
12.2.4 South America Neurofibromatosis Type 1 Market Forecast (2021-2025)
12.2.5 Middle East & Africa Neurofibromatosis Type 1 Market Forecast (2021-2025)
12.3 Neurofibromatosis Type 1 Market Forecast by Type (2021-2025)
12.3.1 Global Neurofibromatosis Type 1 Sales Forecast by Type (2021-2025)
12.3.2 Global Neurofibromatosis Type 1 Market Share Forecast by Type (2021-2025)
12.4 Neurofibromatosis Type 1 Market Forecast by Application (2021-2025)
12.4.1 Global Neurofibromatosis Type 1 Sales Forecast by Application (2021-2025)
12.4.2 Global Neurofibromatosis Type 1 Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Neurofibromatosis Type 1 Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neurofibromatosis Type 1 by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neurofibromatosis Type 1 Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Neurofibromatosis Type 1 Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 9. AstraZeneca Neurofibromatosis Type 1 Major Business
Table 10. AstraZeneca Neurofibromatosis Type 1 Total Revenue (USD Million) (2018-2019)
Table 11. AstraZeneca SWOT Analysis
Table 12. AstraZeneca Neurofibromatosis Type 1 Product and Services
Table 13. AstraZeneca Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. Merck Basic Information, Manufacturing Base and Competitors
Table 15. Merck Neurofibromatosis Type 1 Major Business
Table 16. Merck Neurofibromatosis Type 1 Total Revenue (USD Million) (2018-2019)
Table 17. Merck SWOT Analysis
Table 18. Merck Neurofibromatosis Type 1 Product and Services
Table 19. Merck Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. Global Neurofibromatosis Type 1 Sales by Manufacturer (2018-2019) (K Units)
Table 21. Global Neurofibromatosis Type 1 Revenue by Manufacturer (2018-2019) (USD Million)
Table 22. Global Neurofibromatosis Type 1 Sales by Regions (2015-2020) (K Units)
Table 23. Global Neurofibromatosis Type 1 Sales Market Share by Regions (2015-2020)
Table 24. Global Neurofibromatosis Type 1 Revenue by Regions (2015-2020) (USD Million)
Table 25. North America Neurofibromatosis Type 1 Sales by Countries (2015-2020) (K Units)
Table 26. North America Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020)
Table 27. North America Neurofibromatosis Type 1 Revenue by Countries (2015-2020) (USD Million)
Table 28. North America Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020)
Table 29. Europe Neurofibromatosis Type 1 Sales by Countries (2015-2020) (K Units)
Table 30. Europe Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020)
Table 31. Europe Neurofibromatosis Type 1 Revenue by Countries (2015-2020) (USD Million)
Table 32. Asia-Pacific Neurofibromatosis Type 1 Sales by Regions (2015-2020) (K Units)
Table 33. Asia-Pacific Neurofibromatosis Type 1 Sales Market Share by Regions (2015-2020)
Table 34. Asia-Pacific Neurofibromatosis Type 1 Revenue by Regions (2015-2020) (USD Million)
Table 35. South America Neurofibromatosis Type 1 Sales by Countries (2015-2020) (K Units)
Table 36. South America Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020)
Table 37. South America Neurofibromatosis Type 1 Revenue by Countries (2015-2020) (USD Million)
Table 38. South America Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020)
Table 39. Middle East & Africa Neurofibromatosis Type 1 Sales by Countries (2015-2020) (K Units)
Table 40. Middle East & Africa Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020)
Table 41. Middle East & Africa Neurofibromatosis Type 1 Revenue by Countries (2015-2020) (USD Million)
Table 42. Middle East & Africa Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020)
Table 43. Global Neurofibromatosis Type 1 Sales by Type (2015-2020) (K Units)
Table 44. Global Neurofibromatosis Type 1 Sales Share by Type (2015-2020)
Table 45. Global Neurofibromatosis Type 1 Revenue by Type (2015-2020) (USD Million)
Table 46. Global Neurofibromatosis Type 1 Revenue Share by Type (2015-2020)
Table 47. Global Neurofibromatosis Type 1 Sales by Application (2015-2020) (K Units)
Table 48. Global Neurofibromatosis Type 1 Sales Share by Application (2015-2020)
Table 49. Global Neurofibromatosis Type 1 Sales Forecast by Regions (2021-2025) (K Units)
Table 50. Global Neurofibromatosis Type 1 Market Share Forecast by Regions (2021-2025)
Table 51. Global Neurofibromatosis Type 1 Sales Forecast by Type (2021-2025) (K Units)
Table 52. Global Neurofibromatosis Type 1 Market Share Forecast by Type (2021-2025)
Table 53. Global Neurofibromatosis Type 1 Sales Forecast by Application (2021-2025)
Table 54. Global Neurofibromatosis Type 1 Market Share Forecast by Application (2021-2025)
Table 55. Direct Channel Pros & Cons
Table 56. Indirect Channel Pros & Cons
Table 57. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Neurofibromatosis Type 1 Picture
Figure 2. Global Sales Market Share of Neurofibromatosis Type 1 by Type in 2019
Figure 3. 10 mg Picture
Figure 4. 25 mg Picture
Figure 5. Neurofibromatosis Type 1 Sales Market Share by Application in 2019
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Others Picture
Figure 9. Global Neurofibromatosis Type 1 Market Status and Outlook (2015-2025) (USD Million)
Figure 10. United States Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Canada Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Mexico Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Germany Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 14. France Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 15. UK Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Russia Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Italy Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 18. China Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Japan Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Korea Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 21. India Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Southeast Asia Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Australia Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 24. Brazil Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Egypt Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Saudi Arabia Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 27. South Africa Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Turkey Neurofibromatosis Type 1 Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Global Neurofibromatosis Type 1 Sales Market Share by Manufacturer in 2019
Figure 30. Global Neurofibromatosis Type 1 Revenue Market Share by Manufacturer in 2019
Figure 31. Top 3 Neurofibromatosis Type 1 Manufacturer (Revenue) Market Share in 2019
Figure 32. Top 6 Neurofibromatosis Type 1 Manufacturer (Revenue) Market Share in 2019
Figure 33. Key Manufacturer Market Share Trend
Figure 34. Global Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 35. Global Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million)
Figure 36. Global Neurofibromatosis Type 1 Revenue Market Share by Regions (2015-2020)
Figure 37. Global Neurofibromatosis Type 1 Revenue Market Share by Regions in 2018
Figure 38. North America Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
Figure 39. Europe Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
Figure 41. South America Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
Figure 42. Middle East & Africa Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020)
Figure 43. North America Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million)
Figure 44. North America Neurofibromatosis Type 1 Sales Market Share by Countries (2015-2020)
Figure 45. North America Neurofibromatosis Type 1 Sales Market Share by Countries in 2018
Figure 46. North America Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 47. North America Neurofibromatosis Type 1 Revenue Market Share by Countries in 2018
Figure 48. United States Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 49. Canada Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 50. Mexico Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Europe Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million)
Figure 52. Europe Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020)
Figure 53. Europe Neurofibromatosis Type 1 Revenue Market Share by Countries in 2019
Figure 54. Germany Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 55. UK Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 56. France Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 57. Russia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 58. Italy Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Asia-Pacific Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million)
Figure 60. Asia-Pacific Neurofibromatosis Type 1 Sales Market Share by Regions 2019
Figure 61. Asia-Pacific Neurofibromatosis Type 1 Revenue Market Share by Regions 2019
Figure 62. China Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 63. Japan Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 64. Korea Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 65. India Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Southeast Asia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 67. South America Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million)
Figure 68. South America Neurofibromatosis Type 1 Sales Market Share by Countries in 2019
Figure 69. South America Neurofibromatosis Type 1 Revenue Market Share by Countries in 2019
Figure 70. Brazil Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 71. Argentina Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 72. Middle East and Africa Neurofibromatosis Type 1 Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. Middle East and Africa Neurofibromatosis Type 1 Sales Market Share by Countries in 2019
Figure 74. Middle East and Africa Neurofibromatosis Type 1 Revenue Market Share by Countries (2015-2020)
Figure 75. Middle East and Africa Neurofibromatosis Type 1 Revenue Market Share by Countries in 2019
Figure 76. Saudi Arabia Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 77. Egypt Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 78. Turkey Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 79. South Africa Neurofibromatosis Type 1 Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Global Neurofibromatosis Type 1 Sales and Growth Rate (2021-2025) (K Units)
Figure 81. Global Neurofibromatosis Type 1 Revenue and Growth Rate (2021-2025) (USD Million)
Figure 82. North America Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units)
Figure 83. Europe Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units)
Figure 84. Asia-Pacific Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units)
Figure 85. South America Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units)
Figure 86. Middle East & Africa Sales Neurofibromatosis Type 1 Market Forecast (2021-2025) (K Units)
Figure 87. Sales Channel: Direct Channel vs Indirect Channel
神経線維腫症治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Neurofibromatosis Treatment Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain op…- 神経皮膚性疾患の世界市場（～2026年） The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord. These disorders are usually genetic and arise due …
- 移動病院の世界市場（～2026年） Mobile hospitals are the medical centers or mini hospitals with all the facilities and fully equipped that can be moved from one place and settle in new place and situation smoothly. Mobile hospitals provide medical services to the patient or the injured person in the critical conditions such as nat…
- 外来患者クリニックの世界市場（～2026年） The outpatient clinics has continued to play a significant role in management of the cognitive behavioral disorders. High-risk situations such as substance abuse, sexual offence, depression, obesity and obsessive-compulsive behavior is becoming a major concern in various countries. Management of hig…
- マイクロホスピタルの世界市場（～2026年） Micro-hospitals are small-scale inpatient facilities on two to three-story buildings built on 20,000 to 50,000-square foot spaces that offer a wide range of medical services in a small, neighborhood setting. They run 24/7, all year long, and commonly have between eight and 10 beds where patients can…